Syed S, Singh J, Elkholy H, Rojnic Palavra I, Tomicevic M, Eric A
Front Public Health. 2025; 13:1463871.
PMID: 40051509
PMC: 11882600.
DOI: 10.3389/fpubh.2025.1463871.
Levi L, Bar-Haim M, Rossum I, Davidson M, Leucht S, Fleischhacker W
Schizophr Bull. 2023; 49(4):903-913.
PMID: 36999551
PMC: 10318873.
DOI: 10.1093/schbul/sbad033.
Mielau J, Reiche S, Moon D, Gross E, Gutwinski S, Betzler F
Front Psychiatry. 2023; 13:1037451.
PMID: 36704748
PMC: 9872100.
DOI: 10.3389/fpsyt.2022.1037451.
Wan X, Eguchi A, Qu Y, Yang Y, Chang L, Shan J
Eur Arch Psychiatry Clin Neurosci. 2022; 272(7):1297-1309.
PMID: 35666299
DOI: 10.1007/s00406-022-01437-1.
Kopustinskiene D, Masteikova R, Lazauskas R, Bernatoniene J
Antioxidants (Basel). 2022; 11(4).
PMID: 35453344
PMC: 9030479.
DOI: 10.3390/antiox11040660.
Examining the Use of Antidepressants for Adolescents with Depression/Anxiety Who Regularly Use Cannabis: A Narrative Review.
Hen-Shoval D, Weller A, Weizman A, Shoval G
Int J Environ Res Public Health. 2022; 19(1).
PMID: 35010782
PMC: 8744706.
DOI: 10.3390/ijerph19010523.
The Importance of Suicide Risk Formulation in Schizophrenia.
Berardelli I, Rogante E, Sarubbi S, Erbuto D, Lester D, Pompili M
Front Psychiatry. 2022; 12:779684.
PMID: 34975579
PMC: 8716825.
DOI: 10.3389/fpsyt.2021.779684.
Cannabis Use, Schizotypy and Kamin Blocking Performance.
Dawes C, Bickerdike A, ONeill C, Pereira S, Waddington J, Moran P
Front Psychiatry. 2021; 12:633476.
PMID: 34887781
PMC: 8649723.
DOI: 10.3389/fpsyt.2021.633476.
Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users.
Zhang X, De Leon J, Crespo-Facorro B, Diaz F
J Biopharm Stat. 2020; 30(5):916-940.
PMID: 32511941
PMC: 9030227.
DOI: 10.1080/10543406.2020.1765371.
Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model.
Seillier A, Martinez A, Giuffrida A
PLoS One. 2020; 15(3):e0230238.
PMID: 32163506
PMC: 7067407.
DOI: 10.1371/journal.pone.0230238.
Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory Analysis.
Giordano G, Tomassini L, Cuomo I, Amici E, Perrini F, Callovini G
Front Psychiatry. 2020; 10:935.
PMID: 31969843
PMC: 6960223.
DOI: 10.3389/fpsyt.2019.00935.
Determining factors for Cannabis use among Moroccans Schizophrenic Patients: A cross sectional study.
Bouri S, Hanane H, Idrissi K, Berraho M, Abdellaoui A, Badiaa L
Avicenna J Phytomed. 2020; 10(1):89-100.
PMID: 31921611
PMC: 6941683.
Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats.
Kozela E, Krawczyk M, Kos T, Juknat A, Vogel Z, Popik P
Mol Neurobiol. 2019; 57(3):1733-1747.
PMID: 31823199
DOI: 10.1007/s12035-019-01831-2.
Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial.
Rains L, Marston L, Hinton M, Marwaha S, Craig T, Fowler D
BMC Med. 2019; 17(1):161.
PMID: 31412884
PMC: 6694526.
DOI: 10.1186/s12916-019-1395-5.
Mobile Intervention for Individuals With Psychosis, Dual Disorders, and Their Common Comorbidities: A Literature Review.
Pennou A, Lecomte T, Potvin S, Khazaal Y
Front Psychiatry. 2019; 10:302.
PMID: 31130884
PMC: 6510170.
DOI: 10.3389/fpsyt.2019.00302.
The Cardiovascular Effects of Marijuana: Are the Potential Adverse Effects Worth the High?.
Subramaniam V, Menezes A, DeSchutter A, Lavie C
Mo Med. 2019; 116(2):146-153.
PMID: 31040502
PMC: 6461323.
Models of Concurrent Disorder Service: Policy, Coordination, and Access to Care.
Wiktorowicz M, Abdulle A, Di Pierdomenico K, Boamah S
Front Psychiatry. 2019; 10:61.
PMID: 30837903
PMC: 6389671.
DOI: 10.3389/fpsyt.2019.00061.
Medication adherence in first episode psychosis: the role of pre-onset subthreshold symptoms.
Daneault J, Maraj A, Lepage M, Malla A, Schmitz N, Iyer S
Acta Psychiatr Scand. 2019; 139(4):336-347.
PMID: 30712261
PMC: 6426680.
DOI: 10.1111/acps.13011.
Ventral hippocampal overexpression of Cannabinoid Receptor Interacting Protein 1 (CNRIP1) produces a schizophrenia-like phenotype in the rat.
Perez S, Donegan J, Boley A, Aguilar D, Giuffrida A, Lodge D
Schizophr Res. 2018; 206:263-270.
PMID: 30522798
PMC: 6525642.
DOI: 10.1016/j.schres.2018.11.006.
Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies.
Sloan M, Grant C, Gowin J, Ramchandani V, Le Foll B
Acta Pharmacol Sin. 2018; 40(3):342-350.
PMID: 30166624
PMC: 6460371.
DOI: 10.1038/s41401-018-0081-z.